Health🇺🇸· 7 hours agoModerna stock jumps 177% after melanoma vaccine trial cuts recurrenceWhy it matters: The late-stage result is the first large mRNA cancer-vaccine success and could widen Moderna beyond its fading Covid business.#Moderna#MelanomaThe Business Times (Singapore), The Straits Times +1